Skip to main
ATXS

Astria Therapeutics (ATXS) Stock Forecast & Price Target

Astria Therapeutics (ATXS) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 50%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Astria Therapeutics Inc is positioned favorably due to the successful preclinical development of STAR-0310, which demonstrates a well-tolerated treatment profile and the potential for enhanced efficacy compared to previous therapies. The company's merger strategy, along with BioCryst's established market presence, enhances its operational capabilities and is expected to generate significant profits in its initial year post-launch. Overall, the positive synergies between its product candidates and the substantial market opportunities are anticipated to drive strategic growth and bolster Astria's financial outlook.

Bears say

The financial outlook for Astria Therapeutics Inc is negatively impacted by the potential for failed or inconclusive clinical trials, which may hinder the advancement of their product candidates, STAR-0215 and STAR-0310. Additionally, the company's ability to secure adequate funding for drug development poses a significant risk, as insufficient capital could obstruct progress through the clinical pathway. Other concerning factors include the uncertain valuation related to possible acquisition dynamics and the necessity to meet clinical milestones to avoid delays in payments from partners such as BioCryst.

Astria Therapeutics (ATXS) has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 50% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Astria Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Astria Therapeutics (ATXS) Forecast

Analysts have given Astria Therapeutics (ATXS) a Buy based on their latest research and market trends.

According to 6 analysts, Astria Therapeutics (ATXS) has a Buy consensus rating as of Feb 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Astria Therapeutics (ATXS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.